UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites
Phase 4
Completed
- Conditions
- RhinitisAllergicPerennial
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 453
- Registration Number
- NCT00521131
Wheal and Flare Reaction During 24 Hours in Allergic Volunteers.
Phase 1
Completed
- Conditions
- Allergy
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- UCB Pharma
- Registration Number
- NCT00521170
Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
Phase 2
Completed
- Conditions
- Cough
- First Posted Date
- 2007-08-27
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT00520754
Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 84
- Registration Number
- NCT00519532
Assess Safety and Efficacy of Lacosamide in Patients With Partial Seizures
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 376
- Registration Number
- NCT00515619
Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 19
- Registration Number
- NCT00505934
An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 186
- Registration Number
- NCT00505687
Brivaracetam as add-on Treatment in Adolescents and Adults Suffering From Epilepsy
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 480
- Registration Number
- NCT00504881
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease
- First Posted Date
- 2007-07-17
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 395
- Registration Number
- NCT00501969
Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects
Phase 3
Completed
- Conditions
- Idiopathic Restless Legs Syndrome
- First Posted Date
- 2007-07-09
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 341
- Registration Number
- NCT00498108
© Copyright 2025. All Rights Reserved by MedPath